Hence, MBL and the lectin pathway seem to be a promising target given that a licensed, powerful, human recombinant inhibitor exits to be added to the scarce armamentarium currently available for prophylaxis of CIN. This evidence concerns the gene MBL2 and cervical squamous intraepithelial neoplasia.